Advertisement

Topics

EU Panel Backs Market Withdrawal of Fenspiride Due to Heart Risk

13:47 EDT 17 May 2019 | Medscape

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee recommended revoking marketing authorizations for fenspiride medicines, preventing them from being marketed in the EU.
News Alerts

Original Article: EU Panel Backs Market Withdrawal of Fenspiride Due to Heart Risk

NEXT ARTICLE

More From BioPortfolio on "EU Panel Backs Market Withdrawal of Fenspiride Due to Heart Risk"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...